



California Drug Safety Notification



Notification Name

U. S. FDA Requires Fluoroquinolone Antibacterial Drug Label Update to Warn of Risk of Permanent Nerve Injury

Notification Date	Notification Details	Notification Recommendation
08/15/13	<p>The U.S. Food and Drug Administration (FDA) has required drug labels and Medication Guides for Levaquin (levofloxacin), Cipro (ciprofloxacin), and other fluoroquinolone antibacterial drugs to be updated with a better description of the <u>potential serious side effect</u> of peripheral neuropathy.</p> <p>The risk is associated with fluoroquinolones taken by mouth or injection only. It is not known to be associated with the topical formulation.</p>	<p><i>Patients should receive a Medication Guide and be advised to contact their health care professional right away if symptoms of peripheral neuropathy develop.</i></p> <p><i>Symptomatic patients should be evaluated and potentially switched to a non-fluoroquinolone antibacterial drug.</i></p>

FOR ADDITIONAL INFORMATION, PLEASE VISIT:

<http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm>